Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists

Biotechnology Advances

Volumn 30, Issue 1, 2012, Pages 251-260

  Peri, Francesco ^a   Piazza, Matteo ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

CD14; Immunotherapeutic; Inflammation; Innate immunity; LPS; MD 2; Sepsis; Toll like receptor 4 (TLR4); Vaccine adjuvant

Indexed keywords

CD14; IMMUNOTHERAPEUTIC; INFLAMMATION; INNATE IMMUNITY; LPS; MD-2; SEPSIS; TOLL-LIKE RECEPTOR 4;

PATHOLOGY;

INTERFERONS;

IMMUNOLOGICAL ADJUVANT; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 4;

BACTERIUM; IMMUNITY; IMMUNOASSAY; POLYSACCHARIDE; PROTEIN; TOXIN;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DEVELOPMENT; HUMAN; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; MOUSE; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG DISCOVERY; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LIPOPOLYSACCHARIDES; MICE; MODELS, MOLECULAR; TOLL-LIKE RECEPTOR 4;

BACTERIA (MICROORGANISMS);

EID: 84855721698     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2011.05.014     Document Type: Review

References (88)

1. Abrahamson S.L., Wu H.M., Williams R.E., Der K., Ottah N., Little R., et al. Biochemical characterization of recombinant fusions of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein. Implications in biological activity. J Biol Chem 1997, 272:2149-2155.
2. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
3. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
4. Asai Y., Hashimoto M., Ogawa T. Treponemal glycoconjugate inhibits Toll-like receptor ligand-induced cell activation by blocking LPS-binding protein and CD14 functions. Eur J Immunol 2003, 33:3196-3204.
5. Beamer L.J., Carroll S.F., Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4angstrom resolution. Science 1997, 276:1861-1864.
6. Beamer L.J., Carroll S.F., Eisenberg D. The BPI/LBP family of proteins: a structural analysis of conserved regions. Protein Sci 1998, 7:906-914.
7. Bettoni I., Comelli F., Rossini C., Granucci F., Giagnoni G., Peri F., et al. Glial TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice. Glia 2008, 56:1312-1319.
8. Beutler B. TLR4 as the mammalian endotoxin sensor. Curr Top Microbiol Immunol 2002, 270:109-120.
9. Beutler B., Du X., Poltorak A. Identification of Toll-like receptor 4 (Tlr4) as the sole conduit for LPS signal transduction: genetic and evolutionary studies. J Endotoxin Res 2001, 7:277-280.
10. Burns M., Jenkins S., Kimbrell M., Balakrishna R., Nguyen T., Abbo B., et al. Polycationic sulfonamides for the sequestration of endotoxin. J Med Chem 2007, 50:877-888.
11. Cao L., Tanga F., Deleo J. The contributing role of CD14 in toll-like receptor 4 dependent neuropathic pain. Neuroscience 2009, 158:896-903.
12. Christ W., Asano O., Robidoux A., Perez M., Wang Y., Dubuc G., et al. E5531, a pure endotoxin antagonist of high potency. Science 1995, 268:80-83.
13. Corradin S.B., Mauel J., Gallay P., Heumann D., Ulevitch R.J., Tobias P.S. Enhancement of murine macrophage binding of and response to bacterial lipopolysaccharide (LPS) by LPS-binding protein. J Leukoc Biol 1992, 52:363-368.
14. Cribbs S.K., Martin G.S. Expanding the global epidemiology of sepsis. Crit Care Med 2007, 35:2646-2648.
15. Cunningham M., Shapiro R., Seachord C., Ratcliffe K., Cassiano L., Darveau R. CD14 employs hydrophilic regions to "capture" lipopolysaccharides. J Immunol 2000, 164:3255-3263.
16. David S. Towards a rational development of anti-endotoxin agents: novel approaches to sequestration of bacterial endotoxins with small molecules. J Mol Recognit 2001, 14:370-387.
17. De Leo J.A., Tawfik V.L., LaCroix-Fralish M.L. The tetrapartite synapse: path to CNS sensitization and chronic pain. Pain 2006, 122:17-21.
18. Dentener M.A., Von Asmuth E.J., Francot G.J., Marra M.N., Buurman W.A. Antagonistic effects of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein on lipopolysaccharide-induced cytokine release by mononuclear phagocytes. Competition for binding to lipopolysaccharide. J Immunol 1993, 151:4258-4265.
19. Dziarski R., Tapping R., Tobias P. Binding of bacterial peptidoglycan to CD14. J Biol Chem 1998, 273:8680-8690.
20. Fan X., Stelter F., Menzel R., Jack R., Spreitzer I., Hartung T., et al. Structures in Bacillus subtilis are recognized by CD14 in a lipopolysaccharide binding protein-dependent reaction. Infect Immun 1999, 67:2964-2968.
21. Figueiredo R., Fernandez P., Mourao-Sa D., Porto B., Dutra F., Alves L., et al. Characterization of heme as activator of Toll-like receptor 4. J Biol Chem 2007, 282:20221-20229.
22. Fiore B., Soncini M., Vesentini S., Penati A., Visconti G., Redaelli A. Multi-scale analysis of the toraymyxin adsorption cartridge. Part II: computational fluid-dynamic study. Int J Artif Organs 2006, 29:251-260.
23. Fitzpatrick F., Wheeler R. The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents. Int Immunopharmacol 2003, 3:1699-1714.
24. Fujita M., Into T., Yasuda M., Okusawa T., Hamahira S., Kuroki Y., et al. Involvement of leucine residues at positions 107, 112, and 115 in a leucine-rich repeat motif of human Toll-like receptor 2 in the recognition of diacylated lipoproteins and lipopeptides and Staphylococcus aureus peptidoglycans. J Immunol 2003, 171:3675-3683.
25. Gegner J., Ulevitch R., Tobias P. Lipopolysaccharide (LPS) signal transduction and clearance. Dual roles for LPS binding protein and membrane CD14. J Biol Chem 1995, 270:5320-5325.
26. Gioannini T.L., Zhang D., Teghanemt A., Weiss J.P. An essential role for albumin in the interaction of endotoxin with lipopolysaccharide-binding protein and sCD14 and resultant cell activation. J Biol Chem 2002, 277:47818-47825.
27. Gough M., Hancock R., Kelly N. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 1996, 64:4922-4927.
28. Gradisar H., Keber M., Pristovsek P., Jerala R. MD-2 as the target of curcumin in the inhibition of response to LPS. J Leukoc Biol 2007, 82:968-974.
29. Gupta D., Wang Q., Vinson C., Dziarski R. Bacterial peptidoglycan induces CD14-dependent activation of transcription factors CREB/ATF and AP-1. J Biol Chem 1999, 274:14012-14020.
30. Gutsmann T., Schromm A.B., Brandenburg K. The physicochemistry of endotoxins in relation to bioactivity. Int J Med Microbiol 2007, 297:341-352.
31. Hamann L., Alexander C., Stamme C., Zahringer U., Schumann R.R. Acute-phase concentrations of lipopolysaccharide (LPS)-binding protein inhibit innate immune cell activation by different LPS chemotypes via different mechanisms. Infect Immun 2005, 73:193-200.
32. Hayashi F., Means T., Luster A. Toll-like receptors stimulate human neutrophil function. Blood 2003, 102:2660-2669.
33. Huber M., Kalis C., Keck S., Jiang Z., Georgel P., Du X., et al. R-form LPS, the master key to the activation ofTLR4/MD-2-positive cells. Eur J Immunol 2006, 36:701-711.
34. Hutchinson M., Zhang Y., Shridhar M., Evans J., Buchanan M., Zhao T., et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 2010, 24:83-95.
35. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5:987-995.
36. Jerala R. Structural biology of the LPS recognition. Int J Med Microbiol 2007, 297:353-363.
37. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007, 13:552-559.
38. Kawamoto T., Ii M., Kitazaki T., Iizawa Y., Kimura H. TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain. Eur J Pharmacol 2008, 584:40-48.
39. Kim J., Lee C., Jin M., Lee C., Paik S., Lee H., et al. Crystal structure of CD14 and its implications for lipopolysaccharide signaling. J Biol Chem 2005, 280:11347-11351.
40. Kim H., Park B., Kim J., Kim S., Lee J., Oh S., et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 2007, 130:906-917.
41. Kobe B., Kajava A. The leucine-rich repeat as a protein recognition motif. Curr Opin Struct Biol 2001, 11:725-732.
42. Lamping N., Dettmer R., Schroder N.W., Pfeil D., Hallatschek W., Burger R., et al. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest 1998, 101:2065-2071.
43. Larrick J., Hirata M., Balint R., Lee J., Zhong J., Wright S. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun 1995, 63:1291-1297.
44. Levy O., Ooi C., Elsbach P., Doerfler M., Lehrer R., Weiss J. Antibacterial proteins of granulocytes differ in interaction with endotoxin. Comparison of bactericidal/permeability-increasing protein, p15s, and defensins. J Immunol 1995, 154:5403-5410.
45. Loppnow H., Libby P., Freudenberg M., Krauss J., Weckesser J., Mayer H. Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS. Infect Immun 1990, 58:3743-3750.
46. Lynn M., Rossignol D., Wheeler J., Kao R., Perdomo C., Noveck R., et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 2003, 187:631-639.
47. Mancek-Keber M., Jerala R. Structural similarity between the hydrophobic fluorescent probe and lipid A as a ligand of MD-2. FASEB J 2006, 20:1836-1842.
48. Martin G.S., Mannino D.M., Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
49. Miller K., Suresh Kumar E., Wood S., Cromer J., Datta A., David S. Lipopolysaccharide sequestrants: structural correlates of activity and toxicity in novel acylhomospermines. J Med Chem 2005, 48:2589-2599.
50. Mitsuzawa H., Wada I., Sano H., Iwaki D., Murakami S., Himi T., et al. Extracellular Toll-like receptor 2 region containing Ser40-Ile64 but not Cys30-Ser39 is critical for the recognition of Staphylococcus aureus peptidoglycan. J Biol Chem 2001, 276:41350-41356.
51. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 2007, 19:3-10.
52. Morrison D.C., Jacobs D.M. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry 1976, 13:813-818.
53. Muhle S.A., Tam J.P. Design of Gram-negative selective antimicrobial peptides. Biochemistry 2001, 40:5777-5785.
54. Mullarkey M., Rose J., Bristol J., Kawata T., Kimura A., Kobayashi S., et al. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003, 304:1093-1102.
55. Noman A., Koide N., Hassan F., I-E-Khuda I., Dagvadorj J., Tumurkhuu G., et al. Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production via down-regulation of MyD88 expression. Innate Immun 2009, 15:33-41.
56. Ohto U., Fukase K., Miyake K., Satow Y. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 2007, 316:1632-1634.
57. Okun E., Griffioen K.J., Lathia J.D., Tang S.C., Mattson M.P., Arumugam T.V. Toll-like receptors in neurodegeneration. Brain Res Rev 2009, 59:278-292.
58. Park B., Song D., Kim H., Choi B., Lee H., Lee J. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009, 458:1191-1195.
59. Peterson A.A., Hancock R.E., McGroarty E.J. Binding of polycationic antibiotics and polyamines to lipopolysaccharides of Pseudomonas aeruginosa. J Bacteriol 1985, 164:1256-1261.
60. Piazza M., Rossini C., Della Fiorentina S., Pozzi C., Comelli F., Bettoni I., et al. Glycolipids and benzylammonium lipids as novel antisepsis agents: synthesis and biological characterization. J Med Chem 2009, 52:1209-1213.
61. Piazza M., Yu L., Teghanemt A., Gioannini T., Weiss J., Peri F. Evidence of a specific interaction between new synthetic antisepsis agents and CD14. Biochemistry 2009, 48:12337-12344.
62. Piazza M., Damore G., Costa B., Gioannini T.L., Weiss J.P., Peri F. Hemin and a metabolic derivative coprohemin modulate the TLR4 pathway differently through different molecular targets. Innate Immun 2011, 17(3):293-301.
63. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
64. Resman N., Gradisar H., Vasl J., Keber M., Pristovsek P., Jerala R. Taxanes inhibit human TLR4 signaling by binding to MD-2. FEBS Lett 2008, 582:3929-3934.
65. Rietschel E., Schletter J., Weidemann B., El-Samalouti V., Mattern T., Zähringer U., et al. Lipopolysaccharide and peptidoglycan: CD14-dependent bacterial inducers of inflammation. Microb Drug Resist 1998, 4:37-44.
66. Rossignol D., Lynn M. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J Endotoxin Res 2002, 8:483-488.
67. Schumann R.R., Leong S.R., Flaggs G.W., Gray P.W., Wright S.D., Mathison J.C., et al. Structure and function of lipopolysaccharide binding protein. Science 1990, 249:1429-1431.
68. Schumann R., Lamping N., Hoess A. Interchangeable endotoxin-binding domains in proteins with opposite lipopolysaccharide-dependent activities. J Immunol 1997, 159:5599-5605.
69. Scott M., Rosenberger C., Gold M., Finlay B., Hancock R. An alpha-helical cationic antimicrobial peptide selectively modulates macrophage responses to lipopolysaccharide and directly alters macrophage gene expression. J Immunol 2000, 165:3358-3365.
70. Scott M., Vreugdenhil A., Buurman W., Hancock R., Gold M. Cutting edge: cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein. J Immunol 2000, 164:549-553.
71. Sha T., Sunamoto M., Kitazaki T., Sato J., Ii M., Iizawa Y. Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur J Pharmacol 2007, 571:231-239.
72. Shimazu R., Akashi S., Ogata H., Nagai Y., Fukudome K., Miyake K., et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999, 189:1777-1782.
73. Slivka P., Shridhar M., Lee G., Sammond D., Hutchinson M., Martinko A., et al. A peptide antagonist of the TLR4-MD2 interaction. Chembiochem 2009, 10:645-649.
74. Stockwell B. Chemical genetics: ligand-based discovery of gene function. Nat Rev Genet 2000, 1:116-125.
75. Stockwell B. Frontiers in chemical genetics. Trends Biotechnol 2000, 18:449-455.
76. Takashima K., Matsunaga N., Yoshimatsu M., Hazeki K., Kaisho T., Uekata M., et al. Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br J Pharmacol 2009, 157:1250-1262.
77. Tanga F.Y., Nutile-McMenemy N., DeLeo J.A. The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy. Proc Natl Acad Sci USA 2005, 102:5856-5861.
78. Tidswell M., Tillis W., Larosa S.P., Lynn M., Wittek A.E., Kao R., et al. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 2010, 38:72-83.
79. Vaara M., Vaara T. Polycations sensitize enteric bacteria to antibiotics. Antimicrob Agents Chemother 1983, 24:107-113.
80. Vincent J.L., Laterre P.F., Cohen J., Burchardi H., Bruining H., Lerma F.A., et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005, 23:400-405.
81. Visintin A., Halmen K., Latz E., Monks B., Golenbock D. Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol 2005, 175:6465-6472.
82. Wasan K., Strobel F., Parrott S., Lynn M., Christ W., Hawkins L., et al. Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels. Antimicrob Agents Chemother 1999, 43:2562-2564.
83. Weersink A., van Kessel K., van den Tol M., van Strijp J., Torensma R., Verhoef J., et al. Human granulocytes express a 55-kDa lipopolysaccharide-binding protein on the cell surface that is identical to the bactericidal/permeability-increasing protein. J Immunol 1993, 150:253-263.
84. Weiss J. Bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP): structure, function and regulation in host defence against Gram-negative bacteria. Biochem Soc Trans 2003, 31:785-790.
85. Wright S., Ramos R., Tobias P., Ulevitch R., Mathison J. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249:1431-1433.
86. Yamada M., Ichikawa T., Ii M., Sunamoto M., Itoh K., Tamura N., et al. Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex-1-ene-1-carboxylate. J Med Chem 2005, 48:7457-7467.
87. Youn H., Saitoh S., Miyake K., Hwang D. Inhibition of homodimerization of Toll-like receptor 4 by curcumin. Biochem Pharmacol 2006, 72:62-69.
88. Zweigner J., Gramm H.J., Singer O.C., Wegscheider K., Schumann R.R. High concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood 2001, 98:3800-3808.